Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Diagnosis of Leptomeningeal Metastasis and the Monitoring of Intrathecal Chemotherapy Efficacy in NSCLC

Not yet recruiting

Conditions: Diagnosis

Interventions: Drug: Pemetrexed

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 60

Registration Number: NCT06346977

Locations: 🇨🇳
Union hospital, Wuhan, Hubei, China

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Phase 2

Recruiting

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Serplulimab
Drug: Bevacizumab Biosimilar HLX04
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2024-03-28

Last Posted Date: 2024-03-28

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 46

Registration Number: NCT06334757

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1

Recruiting

Conditions: Thoracic Tumors
Non-small Cell Lung Cancer

Interventions: Drug: AMG 193
Drug: Carboplatin
Drug: Sotorasib
Drug: Paclitaxel
Drug: Pembrolizumab
Drug: Pemetrexed

First Posted Date: 2024-03-27

Last Posted Date: 2025-05-22

Lead Sponsor: Amgen

Target Recruit Count: 500

Registration Number: NCT06333951

Locations: 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Translational Research in Oncology US Inc, Trio Central Pharmacy, Los Angeles, California, United States

and more 61 locations

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

Phase 2

Not yet recruiting

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Lenvatinib
Drug: Pemetrexed
Drug: Cisplatin/Carboplatin
Drug: Pembrolizumab

First Posted Date: 2024-03-19

Last Posted Date: 2024-03-19

Lead Sponsor: Hyogo Medical University

Target Recruit Count: 25

Registration Number: NCT06318286

Locations: 🇯🇵
Hyogo Medical University Hospital, Nishinomiya, Hyogo, Japan

The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

Phase 2

Recruiting

Conditions: NSCLC

Interventions: Drug: pemetrexed

First Posted Date: 2024-03-18

Last Posted Date: 2024-03-18

Lead Sponsor: Jiangsu Province Nanjing Brain Hospital

Target Recruit Count: 20

Registration Number: NCT06315686

Locations: 🇨🇳
Nanjing Brain Hospital, Suzhou, Jiangsu, China

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Sacituzumab tirumotecan
Biological: Pembrolizumab
Drug: Cisplatin
Drug: Rescue medication
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2024-03-15

Last Posted Date: 2025-05-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 780

Registration Number: NCT06312137

Locations: 🇺🇸
Indiana University Health Arnett Cancer Center ( Site 0076), Lafayette, Indiana, United States
🇺🇸
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood, Kentucky, United States
🇺🇸
Mercy Research - David C. Pratt Cancer Center ( Site 0006), Saint Louis, Missouri, United States

and more 201 locations

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis from Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Not Applicable

Recruiting

Conditions: Leptomeningeal Metastasis

Interventions: Drug: Osimertinib
Drug: Pemetrexed

First Posted Date: 2024-03-12

Last Posted Date: 2025-03-21

Lead Sponsor: Guangzhou Medical University

Target Recruit Count: 100

Registration Number: NCT06304441

Locations: 🇨🇳
The Third People's Hospital of Huizhou (Huizhou Hospital of Guangzhou Medical University), Huizhou, Guangdong, China

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Biological: Sacituzumab tirumotecan
Drug: Pemetrexed
Drug: H1 Receptor Antagonist
Drug: Carboplatin
Drug: H2 Receptor Antagonist
Drug: Acetaminophen (or equivalent)
Drug: Dexamethasone (or equivalent)
Drug: Steroid Mouthwash (dexamethasone or equivalent)

First Posted Date: 2024-03-12

Last Posted Date: 2025-05-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 520

Registration Number: NCT06305754

Locations: 🇺🇸
Kaiser Permanente - Oakland ( Site 0054), Oakland, California, United States
🇺🇸
Kaiser Permanente - Roseville ( Site 0055), Roseville, California, United States
🇨🇦
Princess Margaret Cancer Centre ( Site 0203), Toronto, Ontario, Canada

and more 145 locations